Pediatric Cancer Studies Triggered by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Aim at Labels, Not at Improved Treatment

被引：0
|
作者：
Rose, K. [1 ]
机构：
[1] Klausrose Consulting, Med Sci, CH-4125 Riehen, Switzerland
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409 SIOP1
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [1] Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals.
    Lythgoe, Mark
    Krell, Jonathan
    Warner, Jeremy Lyle
    Desai, Aakash
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Impact of the Food and Drug Administration (FDA)-European Medicines Agency (EMA) Common Commentary (CC) on Paediatric Cancer Drug Development
    Reaman, G.
    Herold, R.
    Norga, K.
    Donoghue, M.
    Casey, D.
    Chuk, M.
    Dinndorf, P.
    Leighton, J.
    Sterba, J.
    Paulo, P.
    Baiardi, P.
    van den Berg, H.
    Carleer, J.
    Suzanne, M.
    Temeck, J.
    Murphy, D.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S212 - S212
  • [3] The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept
    Mogielnicki, Mariusz
    Swieczkowski, Damian
    Bachorski, Witold
    Zuk, Grzegorz
    Gilis-Malinowska, Natasza
    Zarzeka, Aleksander
    Merks, Piotr
    Gruchala, Marcin
    Jaguszewski, Milosz
    CARDIOLOGY JOURNAL, 2016, 23 (05) : 515 - 517
  • [4] Differences in immune checkpoint inhibitor (ICI) approvals made by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for thoracic malignancies
    Rizwan, N.
    Pottinger, D.
    Singh, R.
    Jatwani, K.
    Khosla, A.
    Michaeli, D. T.
    Michaeli, T.
    Warner, J.
    Lythgoe, M. P.
    Khaki, A. R.
    Desai, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S156 - S156
  • [5] Antineoplastic drug approvals by European Medicines Agency (EMA) and Food and Drug Administration (FDA) between 2018-2021. Evaluation of potential differences
    Alcubilla, P.
    Arellano, L.
    Aparicio, L.
    Burunat, L.
    Sanchez, C.
    Saez-Penataro, J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S19 - S19
  • [6] Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
    Khanna, Sanjay
    Sarwar, Naveed
    Caldwell, Reece
    Krell, Jonathon
    Benjamin, David Joseph
    Hadfield, Matthew James
    Khaki, Ali Raza
    Warner, Jeremy Lyle
    Lythgoe, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 432 - 432
  • [7] A REVIEW OF POLICIES REGARDING PATIENT-REPORTED OUTCOMES (PRO) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) AND EUROPEAN MEDICINES AGENCY (EMA)
    Liu, Y. S.
    Liang, Y.
    Shao, Q.
    Rascati, K.
    VALUE IN HEALTH, 2020, 23 : S320 - S320
  • [8] COMPARISON OF APPROVAL DATES OF NEW SUBSTANCES BETWEEN THE UNITED STATES OF AMERICA (FOOD AND DRUG ADMINISTRATION, FDA) AND EUROPE (EUROPEAN MEDICINES AGENCY, EMA)
    Batscheider, A.
    Weiss, K.
    Schnauffer, D.
    Al-Khalaf, A.
    Greiner, R. A.
    Shlaen, E.
    VALUE IN HEALTH, 2023, 26 (12) : S293 - S293
  • [9] Assessment of antineoplastic drug approvals by european medicines agency (ema) and food and drug administration (fda) during 2018. Evaluation of possible differences and available evidence
    Alcubilla-Prats, P.
    Marfa, M.
    de Dios, M. V.
    Calvo, G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S20 - S20
  • [10] COMPARISON OF APPROVAL DATES OF NEW MEDICATIONS BETWEEN EUROPE (EUROPEAN MEDICINES AGENCY, EMA), JAPAN (PHARMACEUTICAL AND MEDICAL DEVICES AGENCY, PMDA), AND THE UNITED STATES (US) OF AMERICA (FOOD AND DRUG ADMINISTRATION, FDA)
    Batscheider, A.
    Shlaen, E.
    Demiya, S.
    Akachi, Y.
    Li, Y.
    Schnauffer, D.
    Rauch, M.
    Greiner, Ra
    Bonduelle, D.
    Becker, M.
    VALUE IN HEALTH, 2024, 27 (12)
12345